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Abstract 
Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically 
benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired 
resistance limits clinical impact. In this study, we investigated the impact of mutations 
on BRCA1 isoform expression and therapeutic response. Cancer cell lines and tumors harboring 
mutations in exon 11 of BRCA1 express a BRCA1-Δ11q splice variant lacking the majority of exon 
11. The introduction of frameshift mutations to exon 11 resulted in nonsense-mediated mRNA 
decay of full-length, but not the BRCA1-Δ11q isoform. CRISPR/Cas9 gene editing as well as 
overexpression experiments revealed that the BRCA1-Δ11q protein was capable of promoting 
partial PARPi and cisplatin resistance relative to full-length BRCA1, both in vitro and in vivo. 
Furthermore, spliceosome inhibitors reduced BRCA1-Δ11q levels and sensitized cells carrying 
exon 11 mutations to PARPi treatment. Taken together, our results provided evidence that 
cancer cells employ a strategy to remove deleterious germline BRCA1 mutations through 
alternative mRNA splicing, giving rise to isoforms that retain residual activity and contribute to 
therapeutic resistance.  
 
 
Introduction 
Germline mutations in the BRCA1 gene are associated with an increased risk of developing 
breast and ovarian cancer (1, 2). Mutations often result in reading frameshifts and nonsense-
mediated mRNA decay (NMD; ref. 3). The BRCA1 protein is essential for efficient homologous 
recombination (HR)-mediated repair of double-stranded DNA breaks (4, 5). Inhibitors of PARP, 
as well as platinum agents, induce double-stranded DNA breaks that are repaired by the HR 
DNA repair pathway (6, 7). Consequently, cells that have defective HR DNA repair, such as those 
with dysfunctional BRCA1 or BRCA2 proteins, are highly sensitive to PARP inhibitor (PARPi) or 
platinum treatments (8–11). 
Although PARP inhibitors have been shown to provide survival improvements, many patients that 
harbor germline BRCA1 or BRCA2 mutations do not gain benefit from PARPi therapy (12–14). In 
addition, many patients that first benefit from either PARPi or platinum therapy develop disease 
progression and resistance (15). PARPi or platinum resistance has been demonstrated to arise 
by a variety of mechanisms, including reversion mutations (16, 17), loss of 53BP1 pathway 
activity (18, 19), expression of hypomorphic BRCA1 proteins (20, 21), and drug efflux (22). 
BRCA1 mRNA isoforms generated by alternative splicing lack specific exons and have been 
shown to be expressed in cells and tissues (23–25). In particular, the relative levels 
of BRCA1 exon 11 splice isoforms differ between normal and cancer tissues and in discrete 
phases of the cell cycle (26–29). These isoforms include BRCA1 full-length (inclusion of all coding 
exons), Δ11 (skipping of exon 11), and Δ11q (partial skipping of exon 11). The BRCA1-
Δ11q isoform derives from use of an alternative exon 11 splice donor site, resulting in the 
exclusion of most exon 11 nucleotides (c.788-4096; Supplementary Fig. S1; refs. 27, 28). In 
human cells and tissues, the BRCA1- Δ11q isoform expression is more readily detectable than 
the BRCA1-Δ11 isoform (26, 29, 30). 
The BRCA1-Δ11 isoform has previously been implicated in both cell death and proliferation in 
mouse studies. Both Brca1-null and Brca1Δ11/Δ11 mice that exclusively express Brca1-Δ11 undergo 
embryonic lethality, but Brca1Δ11/Δ11 embryos die at a later stage, suggesting that Brca1-Δ11 
isoform can partially compensate for the lack of other Brca1 isoforms during embryogenesis (31–
33). BRCA1 mutations located in exon 11 represent approximately 30% of the overall number of 
mutation carriers that develop breast and ovarian cancer in the United States (34–37). Here, we 
examined the impact of exon 11 mutations on BRCA1 isoform expression and therapy response. 
 
 
Materials and Methods 
Cell lines and reagents 
Cells were purchased from Asterand or ATCC. Cycloheximide (CHX), actinomycin D (ACT), 
puromycin, blasticidin, and DMSO were purchased from Sigma-Aldrich, cisplatin was from 
APP/Fresenius Kabai USA LLC, and paclitaxel from Sagent Pharmaceuticals. Pladienolide B (Pl-
B) was purchased from Calbiochem. Clovis Oncology provided rucaparib (CO-338) and olaparib 
(AZD2281) was purchased from Selleckchem. BRCA1-mutated cell lines were validated through 
DNA sequencing and the identification of specific BRCA1 mutations that are uniquely present in 
individual cell lines as well as DNA fingerprinting. Cell lines tested negative for mycoplasma. 
Colony formation assays 
Depending on colony-forming potential, cells were seeded at a density ranging from 500 to 4,000 
cells per well in 6-well plates in the presence of increasing concentrations of either rucaparib or 
olaparib. For cisplatin and taxol treatments, exponentially growing cells were cultured in 24-well 
plates, treated with increasing concentrations of cisplatin and taxol for 24 hours, and replated in 
6-well plates for colony formation. For shRNA or cDNA add back colony formation experiments, 
cells were treated as above, but with the addition of either puromycin or blastcitidin in the media. 
For siRNA treatments, exponentially growing cells were reverse transfected in 24-well plates, 
and 2 days after transfection, cells were treated with rucaparib for 72 hours and then replated in 
6-well plates for colony formation. For Pl-B colony assays, cells were treated with Pl-B (1.25 
nmol/L) and rucaparib (100 nmol/L) for 72 hours and then replated into 6-well plates for colony 
formation. Colony formation was assessed 2 weeks postplating with crystal violet staining. Mean 
colony formation from three experiments was expressed as percentage of colonies ± SE relative 
to vehicle-treated cells. 
Gene sequencing and RT-PCR analysis 
Genomic DNA was isolated from cells using the DNeasy tissue kit (Qiagen). To determine 
whether gene rearrangements had taken place that would have excluded the exon 11q region 
from genomic DNA of cell lines and patient-derived xenograft (PDX) tumors, we carried out PCR 
using OneTaq Hot Start 2X Master Mix (NEB) and gDNA as templates. Primers were located in 
exon 10 (forward, F) and 12 (reverse, R): F:aatcacccctcaaggaacca; R:ctcacacccagatgctgcttc. 
Total RNA was isolated from cell lines using RNeasy Kit (Qiagen). For quantitative RT-PCR, 
RNA was tested for quality on a Bioanalyzer (Agilent). RNA concentrations were determined with 
a spectrophotometer (NanoDrop; Thermo Fisher Scientific). RNA was reverse transcribed using 
Moloney murine leukemia virus reverse transcriptase (Ambion) and a mixture of anchored oligo-
dT and random decamers. Two reverse transcription reactions were performed for each sample 
using either 100 or 25 ng of input RNA. Assays were used in combination with TaqMan Universal 
Master mix or Power SybrGreen Master Mix and run on a 7900 HT sequence detection system 
(Applied Biosystems). Cycling conditions were 95°C, 15 minutes, followed by 40 (two-step) 
cycles (95°C, 15 seconds; 60°C, 60 seconds). Ct (cycle threshold) values were converted to 
quantities (in arbitrary units) using a standard curve (four points, 4-fold dilutions) established with 
a calibrator sample. For each sample, the values were averaged and SD of data derived from 
two independent PCRs. For the BRCA1 splice variants, amplicons quantified by on-chip 
electrophoresis on an Agilent 2100 Bioanalyzer were used for absolute quantification assays. 
Primers that specifically recognize the following BRCA1 mRNA isoforms were used: exon +11 
containing: F:tagcaaggagccaacataacagat; R:cttattccattcttttctctcacacag; Δ11q: 
F:gattctgcaaaaaaggctgct; R:cagatgctgcttcaccctga. 
For RBFOX2 F:aagcccagtagttggagctgt, R:ttgcctagggacacatctgctt; and POLR2F: 
F:tgccatgaaggaactcaagg R: tcatagctcccatctggcag. BRCA1 expression values were routinely 
normalized to a POL2RF housekeeping gene (HKG) control and expressed as a percentage of 
the values calculated for MDA-MB-231 cells or to a relevant control sample. 
BRCA1-minigene generation and analysis 
Genomic DNA derived from blood lymphocytes of healthy individuals was tested for the absence 
of mutations by BROCA sequencing. The entire genomic region of BRCA1 from exon 8 to exon 
12 was amplified with the following 5 PCR reactions and primer sets: 
 
 1F: ccgctcgagAACCTTGGAACTGTGAGAACTCTG 
 1R: ccggatatCAATTTGAGAGCCCAGTTTGAAT 
 2F: ccgctcgagAACCTGGGTGACAGAGCAAGA 
 2R: ccggatatcAGGGAAAAGACAGAGTCCTAATAAGA 
 3F: ccgctcgagAGAGCTAAAATGTTTGATCTTGGTC 
 3R: ccggatatcTCTTGATAAAATCCTCAGGATGAAG 
 4F: ccgctcgagATTTGGGAAAACCTATCGGAAG 
 4R: ccggatatcTAATACTGGAGCCCACTTCATTAGT 
 5F: ccgctcgagCCAGCTCAAGCAATATTAATGAAGT 
 5R: ccggatatcGTTAAAATGTCACTCTGAGAGGATAGC 
 
 
HA-tag was cloned into pENTRA vector using SalI and XhoI sites. Each BRCA1 fragment was first 
cloned into pENTRA-HA vector using XhoI (shown in lowercase forward primers above) 
and EcoRV (shown in lowercase reverse primers above) sites. The 5 cloned fragments were 
assembled into a minigene using the following restriction sites that corresponded with cut sites in 
each fragment: EcoRI, SpeI, StuI, and ScaI sites. An eGFP fragment was cloned into the 3′end of 
the exon 12 fragment using EcoRV site. The minigene was then shuttled into pcDNA6.2 
Destination vector using the LR Clonase system (Invitrogen). We confirmed by Sanger 
sequencing that mutations were not introduced into exons or introns within 500 bp flanking each 
exon. The indicated mutations (see Supplementary Fig. S3A) were introduced using site-directed 
mutagenesis (Agilent) using the following primers: 
 
 2288delT F: ccagtgaacttaaagaatttgtcaacctagccttccaaga 
 2288delT R: tcttggaaggctaggttgacaaattctttaagttcactgg 
 2529C>T F: caaatgctgcacactaactcacacatttatttggttctgtttttg 
 2529C>T R: caaaaacagaaccaaataaatgtgtgagttagtgtgcagcatttg 
 3960C>T F: ctaaggtgatgttcctaagatgcctttgccaatattacc 
 3960C>T R: ggtaatattggcaaaggcatcttaggaacatcaccttag 
 1stFOXMut F: tcagggtagttctgtttcaaacttacacgtggagccatgtg 
 1stFOXMut R: cacatggctccacgtgtaagtttgaaacagaactaccctga 
 2ndFOXMut F:gagtaataaactgctgttctcgtgttgtaatgagctggcatgagta 
 2ndFOXMut R: tactcatgccagctcattacaacacgagaacagcagtttattactc 
 Ex11qsplice F: tgcaagtttgaaacagaactcccctgatacttttctggatg 
 Ex11qsplice R: catccagaaaagtatcaggggagttctgtttcaaacttgca 
 
To measure BRCA1-Δ11q-reporter expression, total RNA was isolated from transfected cells 
using RNeasy Kit (Qiagen). cDNA was synthesized using High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). PCR was performed using OneTaq Hot Start 2X Master 
Mix (NEB). Primers that specifically recognize BRCA1-Δ11q-reporter mRNA were: F: 
gattctgcaaaaaaggctgct; R: agtcgtgctgcttcatgtggt; and BSD: F: gcctttgtctcaagaagaatcca; R: 
tagccctcccacacataacca. In addition, Western blots using HA antibody detected BRCA1-Δ11q-
reporter protein expression. 
Western blotting 
Western blotting was carried out as described previously and proteins detected using the 
following antibodies: BRCA1: N-terminal: (MS110, EMD), C-terminal: (D9, Santa Cruz 
Biotechnology), BRCA1 (9010, Cell Signaling Technology), tubulin (2148, Cell Signaling 
Technology), HA (23675, Cell Signaling Technology), RAD51 (H-92, Santa Cruz Biotechnology), 
Pol II [C-18, (Santa Cruz Biotechnology)], CtIP (A300-438-A, Bethyl Laboratories), PALB2 (A301-
247A1, Bethyl Laboratories), BARD1 (A300-263A, Bethyl Laboratories), and BRCA2 (OP-95, 
EMD). HA (23675, Cell Signaling Technology) antibody was used for immunoprecipitation of HA-
BRCA1 complexes from 2 mg of nuclear extract using Pierce Classic IP Kit (Thermo Scientific) 
according to the manufacturer's instructions. Nuclear extracts were derived using NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to the 
manufacturer's instructions. Densitometric analyses were carried out using ImageJ software. 
Immunofluorescence and microscopy 
For immunofluorescence HA (HA.11, Covance), BRCA1 (MS110, EMD), γ-H2AX (pS139; N1-
4131, EMD) and RAD51 (H-92, Santa Cruz Biotechnology), geminin (10802-1-AP, ProteinTech 
Group) and geminin (Abnova, E7071-1A8) antibodies were followed by secondary antibodies 
conjugated to FITC or Texas Red (Jackson ImmunoResearch Laboratories). We acquired 
immunofluorescence images using Nikon NIU Upright Fluorescent Microscope and generated 
images using Nikon NIS Elements software. For IR experiments, we routinely fixed cells 8 hours 
after treatment with 10 Gy. For analyses, we counted a minimum of 200 cells per condition or cell 
line. Foci-positive cells were expressed as a percentage of geminin-positive cells to account for 
any differences in S–G2–M populations between cell lines. Each experiment was carried out 
three times with biologic replicates. γ-H2AX IRIF was present equally in all cell lines and routinely 
measured as a positive control for IRIF. 
Immunofluorescence and immunohistochemical analyses of tumors 
For BRCA1 focus formation analysis, tissue sections were deparaffinized with xylene and 
hydrated with decreasing concentrations of ethanol. For target antigen retrieval, sections were 
microwaved in Dako Antigen Retrieval Buffer pH 9.0 for 4 minutes at 110°C [a T/T MEGA 
multifunctional Microwave Histoprocessor (Milestone)]. Sections were cooled down in distilled 
water for 5 minutes, and then permeabilized with Dako Wash Buffer containing Tween 20 for 5 
minutes, followed by incubation in blocking buffer (Dako Wash Buffer with 1% BSA) for 5 
minutes. Primary antibodies were diluted in Dako Antibody Diluent and incubated at room 
temperature for 1 hour [anti-BRCA1 Abcam MS110 diluted 1:200; anti-Geminin (ProteinTech 
Group, 10802-1-AP, diluted 1:400)]. Sections were washed for 5 minutes in Dako Wash Buffer 
followed by 5 minutes in blocking buffer. Secondary antibodies (Alexa Fluor 488 or 568) were 
diluted 1:500 in blocking buffer and incubated for 30 minutes at room temperature. The two-step 
washing was repeated followed by 5 minutes incubation in distilled water. Dehydration was 
performed with increasing concentrations of ethanol. Sections were mounted with DAPI ProLong 
Gold antifade reagent and stored at −20°C. For analyses, tumors from 2 mice per treatment 
group were analyzed and counted. For each tumor, a minimum of 100 geminin-positive cells 
were identified and counted for those that had at least 5 BRCA1 foci. BRCA1 foci–positive cells 
were calculated as a percentage of geminin-positive cells. 
For assessment of Ki-67 and γ-H2AX by IHC, slides were deparaffinized and hydrated. Antigen 
retrieval was performed using pH 9 EDTA buffer (DAKO, S2368). Endogenous peroxidases were 
quenched by immersion of slides in 3% hydrogen peroxide solution (30% H2O2, Fisher BP2633-
500, diluted in methanol). Primary antibody Ki-67 (Clone EP5), Epitomics, (1:1,500), or γ-H2AX 
(pS139; N1-4131, EMD; 1,20,000) were diluted with DaVinci Green Diluant (Biocare Medical, 
PD900) and incubated on slides overnight at 4 degrees in a humidified slide chamber. Slides 
were then washed 3 times in TBST and incubated with Envision+ System HRP Labelled Polymer 
Anti-Rabbit (Dako, K4003) for 1 hour at room temperature. Specimens were washed 3 times in 
TBST and then developed with DAB solution (Dako, K3468) and counterstained in Meyer 
Hematoxylin (Dako, S3309). For analyses of Ki67 and γ-H2AX expression, a minimum of 2 
tumors derived from 2 separate mice were used. Mice were treated with rucaparib 150 mg/kg two 
times per day for 4 continuous days. For cisplatin, mice were treated with a single dose of 6 
mg/kg. Tumors were resected and formalin fixed 4 days from the first dose. A minimum of 2 
tumors and 3 images per tumor were used to calculate staining intensities. Image staining 
intensities were measured using ImageJ analysis software. 
PDX tumor derivation, xenograft treatments, and analyses 
For PDXs, patient consent for tumor use in animals was completed under a protocol approved by 
the Vall d'Hebron Hospital Clinical Investigation Ethical Committee and Animal Use Committee. 
Mice were maintained and treated in accordance with institutional guidelines of Vall d'Hebron 
University Hospital Care and Use Committee. Tumors were subcutaneously implanted in 6-week-
old female HsdCpb:NMRI-Foxn1nu mice (Harlan Laboratories). Animals were supplemented with 1 
μmol/L estradiol (Sigma) in the drinking water. Upon xenograft growth, tumor tissue was 
reimplanted into recipient mice, which were randomized upon implant growth. Mice were 
allocated in control/treated groups to deliver similar mean and SE when tumor volume reached 
between 150 and 300 mm3 without any blinding. Vehicle or olaparib was administered at 50 
mg/kg per oral gavage 6 days per week. Tumor xenografts were measured with calipers and 
tumor volumes were determined using the formula: (length × width2). At the end of the 
experiment, animals were killed by CO2 inhalation. Tumor volumes are plotted as mean ± SEM. 
Relative tumor volume RTV for vehicle-treated mice and individual RTVs are shown for olaparib-
treated mice. For xenograft studies, MDA-MB-436 cells were subcutaneously implanted in 6-
week-old female NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). When tumors reached approximately 
300 mm3, tumors were harvested and cut up into smaller pieces followed by subcutaneous 
reimplantation. Treatment was initiated when tumors reached between 150 and 180 mm3. 
Rucaparib was administered at 150 mg/kg twice daily for 10 continuous days with a 2-day break 
after the first 5 days. Cisplatin was administered at a single dose of 6 mg/kg. Tumors were 
measured with calipers and tumor volumes calculated as described above. Measurements were 
carried out every 2 days and mice were euthanized when tumors reached 1,500 mm3 in 
accordance with institutional guidelines of Fox Chase Cancer Center (Philadelphia, PA). 
Statistical analyses 
Mean and SE values were compared using unpaired t tests (GraphPad Software). P < 0.05 was 
considered statistically significant. Asterisks indicate statistically significant P values. There were 
similar variances between statistical groups compared. All statistical tests were unpaired t tests 
unless otherwise stated next to the P value. 
 
 
Results 
Cell lines with exon 11 mutations express BRCA1-Δ11q 
To examine the impact of BRCA1 exon 11 mutations on the expression of BRCA1 proteins, we 
employed a panel of human cancer cell lines that were either BRCA1 wild-type or harbored 
known deleterious BRCA1 mutations (Supplementary Fig. S2A). Full-length BRCA1 protein was 
detectable in MDA-MB-231, MCF7, and MDA-MB-468 wild-type BRCA1 cell lines, but was absent 
in all BRCA1 mutation–containing cell lines. A band corresponding with the predicted molecular 
weight (∼89 kDa) of the BRCA1-Δ11q isoform was present in BRCA1 wild-type cell lines, as well 
as L56Br-C1, SUM149PT, and UWB1.289 cell lines that harbored BRCA1 exon 11 frameshift 
mutations (Fig. 1A). 
To establish the identity of the isoform detected below the 100-kDa mark, we transfected cells 
with a siRNA designed to specifically target BRCA1-Δ11q and measured protein expression. 
BRCA1-Δ11q siRNA did not impact the levels of the full-length, but dramatically reduced the 
expression of the predicted BRCA1-Δ11q isoform (Fig. 1B). Furthermore, we confirmed that cells 
did not harbor secondary BRCA1 reversion mutations or genomic rearrangements 
(Supplementary Fig. S2). 
Next, we investigated the levels of BRCA1 mRNA containing exon 11 (+11) as well as the BRCA1-
Δ11q (Δ11q) isoform expression. L56Br-C1, SUM149PT, and UWB1.289 exon 11–mutant cell 
lines exhibited 3- (P < 0.001), 3- (P < 0.001), and 2.9-fold (P < 0.001) lower expression of +11 
transcripts, respectively, relative to MDA-MB-231 cells (Fig. 1C). In contrast, relative Δ11q 
expression was 1.46- (P = 0.0148), 1.55- (P < 0.001), and 1.58-fold (P = 0.0136) higher in L56Br-
C1, SUM149PT, and UWB1.289, respectively, relative to MDA-MB-231 cells expression levels 
(Fig. 1C). 
Robust BRCA1 gene transcription promotes BRCA1-Δ11q expression 
To investigate the impact of germline mutations on exon 11 splicing, we introduced a series of 
exon 11 frameshift mutations into a BRCA1-minigene system (Supplementary Fig. S3). Mutation 
of the exon 11q splice junction disrupted Δ11q-reporter mRNA and protein expression. However, 
three different frameshift mutations at various locations throughout exon 11 had no effect on 
Δ11q-reporter expression (Fig. 1D). Moreover, RNA-seq analyses of mRNA splice junctions did 
not indicate that higher levels of BRCA1-Δ11q expression in cell lines with exon 11 mutations 
were due to increased global alterations in splicing (Supplementary Table S1). 
To further investigate the effects of exon 11 mutations on BRCA1-Δ11q levels, we used 
CRISPR/Cas9 technology to generate SUM149PT cells that either had additional out of frame 
mutations, or reversion mutations that restored the reading frame (Supplementary Fig. S4). In 
line with minigene data, the introduction of additional out-of-frame or frame-restoring mutations in 
exon 11 did not affect BRCA1-Δ11q expression (Fig. 1E). However, clones 3 and 4 that had 
restored BRCA1 reading frames, expressing the BRCA1-long-form protein product, had 2.5- (P < 
0.0001) and 2.47-fold (P < 0.0001) increased levels of +11 expression, respectively, relative to 
sg_GFP control cells (Fig. 1E), likely resulting from premature translation termination codon 
(PTC) removal, enabling +11 containing transcripts to avoid NMD (3). 
We confirmed that NMD contributed to the low levels of +11 mRNA detected in exon 11 mutation 
containing cell lines by treating cells with CHX, an inhibitor of NMD (Fig. 1F; ref. 38). CHX 
treatment for 5 hours resulted in a 2.8- (P = 0.0007), 3.2- (P = 0.023), and 2.9-fold (P = 0.0024) 
increase in +11 levels in L56Br-C1, SUM149PT, and UWB1.289 exon 11–mutant cell lines, 
respectively, but did not affect +11 levels in wild-type MDA-MB-231 cells, or Δ11q mRNA levels 
in any of the cell lines (Fig. 1F). 
The increase in +11 mRNA resulting from inhibition of NMD led us to predict that exon 11–
mutant cell lines have robust BRCA1 gene transcription. To test this possibility, we treated cells 
with the transcription inhibitor ACT and measured BRCA1 mRNA levels. MDA-MB-231 cells 
treated with ACT had a 1.4-fold (P = 0.0002) reduction in +11 mRNA levels compared with 
vehicle-treated cells. However, ACT treatment reduced +11 levels 3-fold (P = 0.0133) in 
SUM149PT cells compared with vehicle-treated cells, and completely abrogated the CHX-
mediated increase in +11 mRNA (Fig. 1G). ACT also reduced Δ11q levels 1.6-fold (P = 0.002) 
and 2-fold (P = 0.021) in MDA-MB-231 and SUM149PT cells, respectively, compared with 
vehicle treatments (Fig. 1H). 
Exon 11–mutant cells demonstrate partial PARPi and cisplatin resistance 
We next measured the ability of exon 11–mutant cells to form BRCA1 and RAD51 
foci. BRCA1 wild-type as well as exon 11–mutant cell lines formed robust BRCA1 and RAD51 γ-
irradiation–induced foci (IRIF). In contrast, BRCA1 and RAD51 IRIF were low or undetectable in 
cells that harbored BRCA1 mutations outside of exon 11 (Fig. 2A). 
SUM1315MO2, HCC1395, and MDA-MB-436 cell lines were highly sensitive to treatment with 
the PARPis rucaparib and olaparib. In contrast, exon 11 mutation containing L56Br-C1, 
SUM149PT, and UWB1.289 cells displayed intermediate PARPi sensitivity. SUM1315MO2, 
HCC1395, and MDA-MB-436 cell lines were also more sensitive to cisplatin treatment compared 
with L56Br-C1, SUM149PT, and UWB1.289 cells. The presence of BRCA1 exon 11 mutations did 
not impact taxol sensitivity (Fig. 2B; Supplementary Table S2). 
In cell growth experiments, BRCA1 wild-type cells continuously cultured in the presence of PARPi 
or cisplatin proliferated at the same rate as vehicle-treated cells (Fig. 2C). Exon 11–mutant cell 
lines proliferated at a reduced rate in the presence of PARPi or cisplatin (Fig. 2C). MDA-MB-436 
and HCC1395 cell lines harbor BRCT domain mutations and lost viability in the presence of 
PARPi or cisplatin. PARPi and cisplatin initially had a greater impact on the proliferation rate of 
UWB1.289 cells, but over time proliferation gradually increased, and corresponded with 
increased expression of BRCA1-Δ11q (Fig. 2D). Importantly, depletion of the BRCA1-Δ11q using 
2 BRCA1 shRNAs reduced RAD51 IRIF 6.8- (P = 0.0021) and 5.7-fold (P = 0.0027) in 
SUM149PT, as well as 6- (P = 0.0014) and 4.7-fold (P = 0.0016) in UWB1.289 cells, compared 
with nontarget (NT) shRNA cells (Fig. 2E). Furthermore, BRCA1 shRNA sensitized SUM149PT 
and UWB1.289 cells to both PARPi and cisplatin treatments (Fig. 2F; Supplementary Table S2). 
BRCA1-Δ11q is functional but inferior to BRCA1 full-length 
To more finely assess the ability of BRCA1-Δ11q to provide resistance to therapy, we used 
CRISPR/Cas9–mediated gene editing to modify BRCA1 in SUM149PT cells (Supplementary Fig. 
S4). SUM149PT cells were subject to an sg_GFP control, or sg_exon11 targeting the mutation-
containing region of exon 11. Mutations introduced by sg_exon11 were either out of frame (out-
frame) or restored the BRCA1 reading frame (in-frame). Moreover, cell lines that expressed 
sg_exon22 demonstrated frameshift mutations in exons 22, resulting in loss of BRCA1-Δ11q 
expression (Fig. 3A and Supplementary Fig. S4). BRCA1-Δ11q expression in sg_exon11–treated 
clones with unrestored reading frames was identical to sg_GFP control cells and there were no 
differences in PARPi and cisplatin sensitivity in colony formation assays. However, sg_exon11 
in-frame clone 3 was 226- (P = 0.0174) and 3.7-fold (P = 0.0009) more resistant to PARPi and 
cisplatin, respectively, and clone 4 was 207- (P < 0.0001) and 3.6-fold (P = 0.0058) more 
resistant to PARPi and cisplatin, respectively, compared with sg_GFP cells. In contrast, 
sg_exon22 cells were 31.4- (P = 0.0183) and 2.3-fold (P = 0.0059) more sensitive to PARPi and 
cisplatin, respectively, compared with sg_GFP cells (Fig. 3B). 
We also compared the ability of ectopic BRCA1 full-length and BRCA1-Δ11q to rescue PARPi 
and cisplatin sensitivity (Fig. 3C). MDA-MB-436 cells harbor a BRCA15396+1G>A mutation that results 
in protein misfolding, undetectable BRCA1 protein and RAD51 IRIF, as well as exquisite PARPi 
and cisplatin sensitivity (20, 39, 40). MDA-MB-436 cells expressing BRCA1 full-length 
demonstrated robust rescue and were 179- (P = 0.0063) and 4.6-fold (P = 0.0002) more resistant 
to PARPi and cisplatin, respectively, compared with mCherry control cells. BRCA1-Δ11q was 
less effective at rescue, and cells were 19- (P = 0.0493) and 2.8-fold (P = 0.0004) more resistant 
to PARPi and cisplatin, respectively, compared with mCherry control cells (Fig. 3D). Moreover, 
when we introduced an L304P mutation (equivalent to L1407P in full-length BRCA1) that blocks 
the BRCA1-PALB2 interaction (41), BRCA1-Δ11q–mediated PARPi and cisplatin rescue was 
abolished (Fig. 3D). 
Both BRCA1 full-length and BRCA1-Δ11q–expressing cells formed BRCA1 and RAD51 IRIF. 
However, BRCA1-Δ11q expressing cells exhibited 1.9- (P = 0.0053) and 1.9-fold (P = 0.0141) 
lower levels of BRCA1 and RAD51 IRIF, respectively, than full-length BRCA1-expressing cells, 
while BRCA1-Δ11q+ L304P–expressing cells had undetectable BRCA1 and RAD51 IRIF (Fig. 
3E). Immunoprecipitation of ectopic BRCA1 from MDA-MB-436 cells suggested that BRCA1-
Δ11q interacted, although less efficiently, with functional protein partners for full-length BRCA1 
(Fig. 3F). We also demonstrated ectopic BRCA1-Δ11q provided therapy resistance in HCC1395 
cells and in a mouse embryonic stem cell system (Supplementary Fig. S5; ref. 42). 
BRCA1-Δ11q promotes resistance in vivo 
To examine the significance of BRCA1-Δ11q expression in tumors, we first measured PARPi 
responsiveness and BRCA1 isoform expression in two individual BRCA1 exon 11–mutant PDX 
models. Despite both PDX models harboring the same BRCA1-exon 11 2080delA mutation 
(Supplementary Fig. S2), PDX124 tumors were sensitive and PDX196 tumors were resistant to 
olaparib treatment (Fig. 4A). We confirmed that tumors did not have reversion mutations or gene 
rearrangements (Supplementary Fig. S2). Similar to exon 11–mutant cell lines, both PDX124 and 
PDX196 expressed higher levels of Δ11q compared with +11 mRNA, relative to MDA-MB-231 
control cells. However, BRCA1 mRNA levels were significantly greater in PDX196 tumors than in 
PDX124 tumors, with 26- (P = 0.0001) and 23-fold (P < 0.0001) higher levels of both +11 and 
Δ11q, respectively (Fig. 4B). BRCA1-Δ11q protein expression was detectable in olaparib-
resistant PDX196 tumors, as well as PDX124 tumors that eventually grew through olaparib 
treatment (Fig. 4C). BRCA1 foci formation was also readily detectable in PDX196 tumors (Fig. 
4D). 
To further assess the impact of BRCA1-Δ11q on therapy resistance in vivo, we utilized the MDA-
MB-436 isogenic cell line panel for xenograft experiments. At 30 days post tumor implantation, 
rucaparib or cisplatin treatment delayed mean tumor growth 6.8- (P < 0.0001) and 12.9-fold (P < 
0.0001), respectively, compared with vehicle-treated mice with mCherry-overexpressing MDA-
MB-436 tumors. In contrast, rucaparib and cisplatin treatment delayed mean tumor growth 1.1-
fold (P = 0.4455) and 1.28-fold (P = 0.2537) in BRCA1 wild-type and 1.4-fold (P = 0.0872) and 
2.3-fold (P = 0.019) in BRCA1-Δ11q–overexpressing tumors, respectively, compared with 
vehicle-treated mice (Fig. 4E and F). 
Kaplan–Meier analyses indicated that the median overall survival (OS) of mice harboring 
mCherry-expressing tumors that were treated with rucaparib or cisplatin increased 1.7-fold (P = 
0.0016, log-rank test) and 2-fold (P = 0.0016, log-rank test), respectively, compared with vehicle 
treated mice. In contrast, in mice harboring BRCA1 wild-type tumors that were treated with 
rucaparib or cisplatin, median OS increased 1.3-fold (P = 0.0071, log-rank test) and 1.4-fold (P = 
0.0048, log-rank test), respectively, and in mice harboring BRCA1-Δ11q tumors treated with 
rucaparib or cisplatin median OS increased 1.2-fold (P = 0.1536, log-rank test) and 1.5-fold (P = 
0.0333, log-rank test), respectively, compared with vehicle-treated mice (Fig. 4G). 
Short-term assessment of pharmacodynamics markers showed that rucaparib increased γ-H2AX 
positivity similarly in all tumors, but wild-type and BRCA1-Δ11q tumors had 4.5- (P < 0.0001) and 
2.2-fold (P = 0.005) lower γ-H2AX positivity, respectively, after cisplatin treatment compared with 
mCherry-expressing tumors. In addition, wild-type and BRCA1-Δ11q tumors treated with 
rucaparib had 2.2- (P = 0.0007) and 2.5-fold (P = 0.0059) higher Ki67 positivity, respectively; and 
tumors treated with cisplatin had 2.6- (P < 0.0001) and 3.7-fold (P = 0.0003) higher Ki67 
positivity, respectively, compared with mCherry-expressing tumors (Fig. 4G). In contrast to in 
vitro data, the degree of PARPi or cisplatin rescue afforded by BRCA1-Δ11q overexpression was 
more similar to BRCA1 full-length in vivo. 
Assessment of BRCA1 exon 11 mutations and patient survival 
Because exon 11–mutant tumors were capable of expressing BRCA1-Δ11q, we assessed survival 
outcomes of patients with frameshift mutations located inside (IE11) versus outside (OE11) of 
exon 11. We analyzed 5-year OS data from the time of initial diagnosis in patients with serous 
ovarian carcinoma from a previously reported study (43). Here, participants 
with BRCA1 frameshift mutations OE11 (n = 231, 43%; 95% CI, 36%–49%) presented better OS 
than noncarriers (n = 1,333, 33%; 95% CI, 30%–36%; P = 0.002, log-rank test) as well as 
participants with frameshift mutations IE11 (n = 148, 31%; 95% CI, 23%–39%; P = 0.02, log-rank 
test) at 5 years of follow up. Moreover, participants with frameshift mutations IE11 presented with 
5-year OS similar to noncarriers (P = 0.84, log-rank test; Fig. 5A, Supplementary Tables S3 and 
S4). 
Although patients with exon 11 mutations demonstrated worse 5-year survival, we hypothesized 
that, similar to our PDX data, BRCA1-Δ11q might only be highly expressed in a fraction of exon 
11–mutant tumors, and so not all exon 11–mutant patients would necessarily be resistant to 
therapy. Analyses of primary tumors (unrelated to the above studies) with mutations IE11 
showed variable levels of BRCA1-Δ11q expression. Tumor #317 expressed 2.7- (P = 0.0227) and 
4-fold (P = 0.0117) greater levels of Δ11q compared with tumor #325 and tumor #411, 
respectively, despite all tumors harboring deleterious exon 11 mutations (Fig. 5B). 
Inhibition of splicing increases PARPi sensitivity 
Because high levels of BRCA1-Δ11q expression were required for residual function, we 
hypothesized that limiting splicing-dependent excision of exon 11q might provide an opportunity 
to enhance PARPi sensitivity. We first identified two binding elements for the FOX2 splicing site 
selection factor at position +18 and +63 downstream from the cryptic splice site location 
(Supplementary Fig. S6; refs. 44, 45). Depletion of FOX2 using 2 individual siRNAs did not impact 
+11 expression levels, but reduced Δ11q expression 1.7- (P = 0.0043) and 1.6-fold (P = 0.0179) 
in MDA-MB-231, 1.5- (P = 0.048) and 1.6-fold (P = 0.0301) in UWB1.289, 2.2- (P = 0.0056) and 
3.1-fold (P = 0.0017) in SUM149PT cells, compared with scrambled siRNA–treated cells, 
respectively (Fig. 6A). At the protein level, densitometric analyses of Western blots indicated 
FOX2 siRNA did not impact full-length BRCA1 protein expression, but BRCA1-Δ11q levels were 
reduced 2.9- and 2.2-fold in MDA-MB-231, 2- and 2.8-fold in UWB1.289, 1.9- and 1.8-fold in 
SUM149PT cells, compared with scrambled siRNA–treated cells (Fig. 6B). FOX2 siRNA had no 
impact on MDA-MB-231 cells PARPi sensitivity, but reduced the LC50 value of rucaparib 3.8- (P = 
0.0063) and 27.4-fold (P = 0.0017) in UWB1.289 cells, as well as 1.9- (P = 0.0237) and 5-fold 
(P = 0.0002) in SUM149PT cells, compared with scrambled siRNA–treated cells (Fig. 6C). 
Furthermore, BRCA1-minigene analyses demonstrated that mutation of FOX2-binding motifs 
also partially decreased Δ11q-reporter mRNA and protein levels (Fig. 6D). 
We next investigated the ability of Pl-B, a small-molecule inhibitor of the U2 snRNP spliceosome 
machinery (46), to disrupt BRCA1-Δ11q production. Pl-B treatment reduced both +11 and Δ11q 
mRNA expression; however, the relative reduction in Δ11q levels was 7.7- (P = 0.002) and 7-fold 
(P = 0.016) greater compared with the reduction in +11 levels in MDA-MB-231 and UWB1.289 
cells, respectively (Fig. 6E). Furthermore, full-length BRCA1 protein levels were reduced but 
remained readily detectable after treatment with up to 10 nmol/L Pl-B in MDA-MB-231 cells. 
However, BRCA1-Δ11q protein levels were barely detectable at 1.25 nmol/L Pl-B in both MDA-
MB-231 and UWB1.289 cells (Fig. 6F). Simultaneous incubation with both Pl-B and rucaparib did 
not significantly impact MDA-MB-231 cells, but resulted in a 2.8- (P = 0.0296) and 2.1-fold (P = 
0.0426) reduction in colony formation compared with cells treated with rucaparib only in 
UWB1.289 and SUM149PT cells, respectively (Fig. 6G). Furthermore, ectopic overexpression of 
a BRCA1-Δ11q cDNA that did not depend on exon 11q splicing, resulted in a 1.9-fold (P = 0.001) 
rescue in colony formation in cells treated with the Pl-B and rucaparib combination, compared 
with GFP-expressing control cells (Fig. 6H), suggesting that Pl-B–induced PARPi sensitization 
was mediated, in part, through the reduction in BRCA1-Δ11q levels. 
 
Discussion 
In the current study, we provide evidence that BRCA1 splice isoforms lacking exon 11 are 
capable of producing truncated but hypomorphic proteins. It was previously shown that the exon 
11–deficient Brca1-Δ11 isoform partially compensates for the lack of other Brca1 isoforms during 
embryogenesis (31–33, 47). Here, we show that BRCA1-Δ11q can also partially compensate for 
full-length BRCA1 in response to homologous recombination targeting therapeutics. BRCA1-
Δ11q retains, although less efficiently, many of the protein–protein interactions carried out by full-
length BRCA1. We identified the BRCA1–Δ11q–PALB2 interaction as critical for BRCA1-Δ11q–
mediated RAD51 IRIF and resistance. 
BRCA1-Δ11q was expressed in BRCA1 wild-type as well as exon 11–mutant cell lines. Although 
frameshift mutations in exon 11 resulted in the NMD of exon 11 containing transcripts, they did 
not impact the rate of alternative splicing or directly affect BRCA1-Δ11q levels. In support of this, 
PDX124 and PDX196 tumors both harbored identical 2080delA exon 11 mutations; however, 
both +11 and Δ11q transcript levels were significantly higher in PDX196 relative to PDX124 
tumors, suggesting that overall BRCA1 gene transcription, rather than the rate of alternative exon 
splicing, was elevated. Both patients whose tumors were used to derive PDX124 and PDX196 
initially demonstrated clinical responsiveness to olaparib therapy; while PDX124 was derived 
prior to the patient starting olaparib therapy, PDX196 was derived at the time of clinical tumor 
progression on olaparib. We anticipate that high levels of BRCA1-Δ11q expression may be 
selected for in response to chemotherapy. Primary patient tumors harboring exon 11 mutations 
also demonstrated variable BRCA1-Δ11q levels, and this isoform might only be overexpressed in 
a subset of exon 11 mutation carriers. Additional resistance mechanisms such as secondary 
reversion mutations have also been shown to occur in tumors with exon 11 mutations (48, 49). 
Intriguingly, our analyses indicated that exon 11 mutation carriers with ovarian cancer had a 
worse 5-year overall survival compared with non-exon 11 mutation carriers (Fig. 5A). Another 
recent study of mutation-specific cancer risks identified the exon 11 region of BRCA1 as an 
ovarian cancer cluster region, where mutation carriers had a relative decrease in breast relative 
to ovarian cancer risk (50). Further work is required to determine whether BRCA1-Δ11q has any 
impact on long-term survival outcomes or breast versus ovarian tissue–specific phenotypes. 
Currently, an understanding of PARPi and platinum resistance is incomplete. Our findings 
provide evidence for a role of the BRCA1-Δ11q alternative splice isoform in promoting 
resistance. Moreover, we show that inhibition of the spliceosome reduced BRCA1-Δ11q levels 
and sensitized exon 11–mutant cell lines to PARPi, potentially offering a strategy to resensitize 
tumors that express high levels of BRCA1-Δ11q. 
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Figure 1.BRCA1 exon 11–mutant cell lines express BRCA1-Δ11q.  
A, cell lines were analyzed for BRCA1 and tubulin levels by Western blot analysis. *, predicted BRCA1 
locations, molecular weights are indicated. B, cells were treated with scrambled (Sc) or BRCA1-Δ11q (11q) 
siRNA and analyzed by Western blot analysis. C, exon 11 containing (+11) BRCA1 transcripts and 
the BRCA1-Δ11q (Δ11q) isoform were detected using qRT-PCR. Values were normalized to a HKG, 
expressed as a percentage of MDA-MB-231 cells. D, 293T cells were transfected with either GFP-control 
or BRCA1-minigene reporter constructs that were wild-type (WT) or carrying mutations that disrupted 
the cryptic 11q splice site (11q), or with frameshift mutations (M1:2288delT; M2:2529C>T; M3:3960C>T). 
BRCA1-Δ11q-reporter mRNA and protein expression was measured by RT-PCR (top) and Western blot 
analysis (bottom); see Supplementary Fig. S3. E, CRISPR/Cas9 targeting the mutation-containing region of 
exon 11 (sg_exon11)-generated SUM149PT clones (C) 1–4; see Supplementary Fig. S4. +11 and Δ11q 
mRNA was measured using qRT-PCR (left); values were normalized to a HKG and expressed as a 
percentage of sg_GFP control cells. BRCA1 protein was detected by Western blot analysis (right). F, the 
indicated cell lines were treated with vehicle or 10 μg/mL CHX for 5 hours, followed by assessment of +11 
(left) and Δ11q (right) levels by qRT-PCR. G, cells were treated with either vehicle (V), 10 μg/mL CHX (C), 5 
μg/mL ACT (A), or A and C simultaneously for 5 hours and assessed for +11 expression by qRT-PCR. H, 
cells were treated with either vehicle (V) or 5 μg/mL ACT (A) for 5 hours and assessed for Δ11q expression 
by qRT-PCR. *, P < 0.05. 
 
 
 
  
Figure 2. Exon 11–mutant cells are less sensitive to PARPi and cisplatin treatment.  
A, cells were untreated (no Rx) or treated with IR (10 Gy) and subject to immunofluorescence to 
detect BRCA1, RAD51, and γ-H2AX foci; representative images of IR-treated cells. Mean ± SEM 
foci-positive cells are expressed as a percentage of total geminin-positive cells. B, cell lines were 
treated with rucaparib, olaparib, cisplatin, or taxol and colony formation assessed; graphs 
represent three independent experiments, mean ± SEM LC50 values; see Supplementary Table 
S2 for fold changes and P values. C, cells were maintained in the presence of vehicle, 100 
nmol/L rucaparib (left), or 20 ng/mL cisplatin (right) and counted every 4 days. Cell line growth 
was expressed as a percentage of vehicle-treated cell numbers counted on the same day. Mean 
± SEM from three technical replicates. D, UWB1.289 vehicle-, rucaparib (R)-, and cisplatin (C)-
treated cell lysates were collected at days 25 and 50 for Western blot analysis. E, assessment of 
BRCA1, RAD51, and γ-H2AX foci by immunofluorescence as for A. Western blot analysis (top) 
shows BRCA1-Δ11q was depleted using two individual BRCA1 targeting shRNAs. 
Representative images (bottom) of IR-treated cells and mean ± SEM foci-positive cells are 
expressed as a percentage of total geminin-positive cells (right). F, cells described in E were 
treated with rucaparib or cisplatin and colony formation assessed; three independent 
experiments, mean ± SEM; LC50 concentrations are shown; see Supplementary Table S2. *, P < 
0.05. 
 
 
  
Figure 3. BRCA1-Δ11q provides partial resistance to therapy in vitro.  
A, CRISPR/Cas9 gene targeting the SUM149PT BRCA1 mutation-containing region of exon 11 
(sg_exon11) did not affect the reading frame (OF) in clones 1, 2, or restored the reading frame 
(IF) in clones 3, 4. Targeting of exon 22 (sg_exon22) resulted in frameshift mutations and loss of 
BRCA1 expression. Cells treated with sg_GFP were used as a control. BRCA1 protein was 
detected by Western blot analysis. See Supplementary Fig. S4 for more details. B, cells 
described in A were treated with rucaparib or cisplatin and colony formation assessed. C, MDA-
MB-436 cells expressing mCherry, BRCA1 full-length, BRCA1-Δ11q, or BRCA1-Δ11q+L304P 
were assessed for BRCA1 protein expression by Western blot analysis. D, cells described in C 
were treated with rucaparib or cisplatin and colony formation assessed. E, cells described in C 
were treated with IR (10 Gy) and subject to immunofluorescence to detect BRCA1, RAD51, and 
γ-H2AX foci, as well as geminin and DAPI staining; representative images of IR-treated cells. 
Double geminin and BRCA1- or RAD51-positive cells were counted and expressed as a 
percentage of total geminin-positive cells; bars show mean ± SEM of geminin+BRCA1 or RAD51 
foci-positive cells from three independent experiments. F, cells described in C were subject to 
immunoprecipitation using an anti-HA antibody and Western blotting with the indicated 
antibodies. *, P < 0.05. 
 
 
  
Figure 4. BRCA1-Δ11q promotes resistance in vivo.  
A, PDX124 (n ≥ 8 mice; left) and PDX196 (n ≥ 3 mice; right) tumors were treated with vehicle 
(black lines) or olaparib (green lines) and tumor volume measured. B, PDX tumors were 
harvested from three individual untreated mice and assessed for +11 and Δ11q expression by 
qRT-PCR. Values were normalized to the POL2RF HKG control and expressed as a percentage 
of the values calculated for MDA-MB-231 cells. C, MDA-MB-231 cells were prepared for whole 
cell extract (WCE) as well as tumor xenografts and used as positive controls, and compared with 
PDX127 (BRCA1185delAG-mutant control, n = 1), PDX196 (n = 2), PDX124 OS (growth inhibition with 
olaparib, n = 1), and OR (growth slowed with olaparib, n = 2) tumors for Western blotting. D, mice 
harboring PDX196 tumors were treated with vehicle or olaparib and tumors assessed for BRCA1 
foci formation as well as geminin staining; representative images (left) and quantification of 
BRCA1 mean ± SEM foci geminin-positive cells. E, MDA-MB-436 tumor xenografts expressing 
mCherry, BRCA1 wild-type, and BRCA1-Δ11q were treated with vehicle (black lines), rucaparib 
(green lines), or cisplatin (red lines) and tumor growth measured; lines represent individual 
tumors and mice (n = 5). F, individual tumor volumes at day 30 are shown. G, Kaplan–Meier 
survival analyses for mice described in E. H, Mice were treated as in E for 4 days, tumors were 
assessed for γ-H2AX and Ki67 staining by IHC. Representative images, scale bars, 50 μm. 
Mean ± SEM quantification of staining intensities. *, P < 0.05. 
 
Figure 5. BRCA1 exon 11 mutations and patient survival.  
A, Kaplan–Meier estimates of cumulative survival according to BRCA1 mutation group of serous 
ovarian cancer patients (see Supplementary Tables S3 and S4). B, primary breast and ovarian 
cancer patient tumors (unrelated to studies described in A) were subject to qRT-PCR analysis for 
+11 and Δ11q expression. Values were normalized to a HKG control and expressed as a 
percentage of the values calculated for MDA-MB-231 cells. *, P < 0.05. 
 
 
 
  
Figure 6. Splicing inhibition sensitizes exon 11–mutant cells to PARPi.  
A, MDA-MB-231, UWB1.289, and SUM149PT cells were transfected with scrambled (Sc) or 
FOX2#1 and FOX2#2 siRNA and FOX2, POLR2F, +11 and Δ11q BRCA1 isoform mRNA levels 
measured by qRT-PCR. Values were normalized to POLR2F HKG expression and expressed as 
a percentage of MDA-MB-231 cells. B, cells treated as in A were subject to Western blotting. C, 
cells treated as in A were subject to 3-day rucaparib and cisplatin exposure and reseeded for 
colony formation. Mean ± SEM. LC50values are shown. D, 293T cells were transfected with 
BRCA1 minigene reporter constructs as in Fig. 1D and Supplementary Fig. S3, with FOX2-
binding sites mutated (FOX). BRCA1-Δ11q-reporter construct mRNA and protein expression was 
measured by RT-PCR (left) and Western blot analysis (right), respectively. E, MDA-MB-231 and 
UWB1.289 cells incubated with Pl-B (10 nmol/L) and mRNA levels measured by qRT-PCR. 
Values were expressed as a percentage of vehicle-treated MDA-MB-231 cells or UWB1.289 
cells. F, cells were treated with increasing concentrations of Pl-B and subject to Western blotting. 
G, cells were treated with vehicle (−) or Pl-B (+; 1.25 nmol/L) and either vehicle or rucaparib (100 
nmol/L) for 72 hours and reseeded for colony formation assay; mean ± SEM colony formation of 
rucaparib-treated cells calculated as a percentage of vehicle-treated cells. H, SUM149PT cells 
engineered to ectopically express GFP or BRCA1-Δ11q were treated as in G and assessed for 
colony formation. Western blot analysis (left) and mean ± SEM colony formation of rucaparib-
treated cells, calculated as a percentage of vehicle-treated cells (right). *, P < 0.05. 
 
